Bristol Myers Squibb Co. has announced a change in its top legal position, appointing Cari Gallman as the new executive vice president, general counsel, and chief policy officer. Gallman, who currently holds the role of executive vice president for corporate affairs, will be succeeding Sandra Leung. Leung is set to retire after a notable 33-year tenure at the pharmaceutical giant. The transition was communicated to employees by CEO Chris Boerner, as noted in a recent article.
Leung will remain with the company for a certain transition period, the length of which has not been disclosed. This leadership shift occurs at a critical time as Bristol Myers Squibb engages in legal proceedings against the federal government regarding rebates linked to its drug, Eliquis. This ongoing litigation emphasizes the prominence of the role Gallman will undertake, influencing the legal strategies and policies moving forward.
Gallman’s elevation to this pivotal role marks a significant phase for Bristol Myers Squibb, linking corporate affairs closely with legal and policy responsibilities. Her seasoned background in corporate matters is expected to support the company’s strategic objectives amidst current regulatory challenges.